Pearl Cohen advises Biolojic Design Ltd. on intellectual property matters on the research collaboration and license agreement with Eli Lilly that will leverage Biolojic's AI-based multibody platform to discover and develop a potential novel antibody-based therapy for the treatment of diabetes.
Mark Cohen, Senior Partner and Chair of the Life Sciences Practice Group represents Biolojic Design, Ltd. in its intellectual property and patent prosecution matters.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.